<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280264</url>
  </required_header>
  <id_info>
    <org_study_id>7580-101</org_study_id>
    <nct_id>NCT03280264</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism</brief_title>
  <official_title>An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in
      patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo
      parathyroidectomy or relapse after parathyroidectomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects whose corrected serum calcium level is maintained ≤ 10.3 mg/dL for 2 weeks in the evaluation period.</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose corrected serum calcium level decreases by ≥1.0 mg/dL from baseline and the decrease is maintained for 2 weeks in the evaluation period.</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected serum calcium level</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intact Parathyroid Hormone (PTH) level</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole PTH level</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Parathyroid Carcinoma</condition>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>KHK7580</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK7580</intervention_name>
    <description>oral administration</description>
    <arm_group_label>KHK7580</arm_group_label>
    <other_name>evocalcet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Personally submitted written voluntary informed consent to participate in the study

          -  Patients with a diagnosis of parathyroid carcinoma or primary hyperparathyroidism who
             are unable to undergo parathyroidectomy or relapse after parathyroidectomy.

          -  Corrected serum calcium level is &gt; 11.3 mg/dL at screening.

        Exclusion Criteria:

          -  Patients receiving cinacalcet hydrochloride within 2 weeks before screening

          -  Patients diagnosed with hypercalcemia associated with malignant tumors other than
             parathyroid carcinoma.

          -  Severe heart disease

          -  Severe hepatic dysfunction

          -  Uncontrolled hypertension and/or diabetes

          -  Treatment with an investigational product (drug or medical device) in a clinical study
             or any study equivalent to clinical study within 12 weeks before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Hakko Kirin Co., Ltd.</last_name>
    <email>clinical.info@kyowa-kirin.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Ōsaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

